TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
President Trump has posted a new announcement on Truth Social, the social media platform. He wrote:
“Today, the CDC Vaccine Committee made a very good decision to END their Hepatitis B Vaccine Recommendation for babies, the vast majority of whom are at NO RISK of Hepatitis B, a disease that is mostly transmitted sexually, or through dirty needles. The American Childhood Vaccine Schedule long required 72 “jabs,” for perfectly healthy babies, far more than any other Country in the World, and far more than is necessary. In fact, it is ridiculous! Many parents and scientists have been questioning the efficacy of this “schedule,” as have I! That is why I have just signed a Presidential Memorandum directing the Department of Health and Human Services to “FAST TRACK” a comprehensive evaluation of Vaccine Schedules from other Countries around the World, and better align the U.S. Vaccine Schedule, so it is finally rooted in the Gold Standard of Science and COMMON SENSE! I am fully confident Secretary Robert F. Kennedy, Jr., and the CDC, will get this done, quickly and correctly, for our Nation’s Children. Thank you for your attention to this matter. MAHA!”
How Will Trump’s Statement Affect the Stock Market?
This latest post has the potential to affect the stock market. That’s because Donald Trump’s statement could lead to increased volatility in the stock prices of pharmaceutical companies like Johnson & Johnson, Merck & Company, and Pfizer Inc, as they are major players in the vaccine market. The potential reevaluation of the U.S. Vaccine Schedule might impact the demand for certain vaccines, affecting the revenue streams of these companies. Consequently, this could also influence the performance of health care and biotechnology ETFs such as Health Care Select Sector SPDR Fund, Vanguard Health Care ETF, and iShares Biotechnology ETF, which have significant exposure to these stocks.
Here are some of the stocks that might be affected:
Johnson & Johnson ((JNJ)),
Merck & Company ((MRK)),
Pfizer Inc ((PFE)),
Health Care Select Sector SPDR Fund ((XLV)),
Vanguard Health Care ETF ((VHT)),
iShares Biotechnology ETF ((IBB)).